Genmab Management

Management criteria checks 4/4

Genmab's CEO is Jan G.J. de Winkel, appointed in Jun 2010, has a tenure of 14.42 years. total yearly compensation is DKK44.30M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth DKK914.35M. The average tenure of the management team and the board of directors is 7.4 years and 7.7 years respectively.

Key information

Jan G.J. de Winkel

Chief executive officer

DKK 44.3m

Total compensation

CEO salary percentage	20.8%
CEO tenure	14.4yrs
CEO ownership	1.0%
Management average tenure	7.4yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jan G.J. de Winkel's remuneration changed compared to Genmab's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	DKK 5b
Jun 30 2024	n/a	n/a	DKK 6b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b

Compensation vs Market: Jan G.J.'s total compensation ($USD6.25M) is about average for companies of similar size in the UK market ($USD5.74M).

Compensation vs Earnings: Jan G.J.'s compensation has been consistent with company performance over the past year.

CEO

Jan G.J. de Winkel (63 yo)

14.4yrs

Tenure

DKK 44,300,000

Compensation

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jan G.J. de Winkel	Co-Founder	14.4yrs	DKK 44.30m	0.99% DKK 914.4m
Anthony Pagano	Executive VP & CFO	4.7yrs	DKK 19.60m	0.011% DKK 10.2m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.8yrs	DKK 10.10m	no data
Christopher Cozic	Executive VP & Chief People Officer	7yrs	DKK 13.20m	no data
Martine van Vugt	Executive VP & Chief Strategy Officer	10.8yrs	DKK 8.90m	no data
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 800.00k	0.00061% DKK 561.8k
Judith Klimovsky	Executive VP & Chief Development Officer	7.8yrs	DKK 21.70m	0.014% DKK 12.7m
Tahamtan Ahmadi	Executive VP	3.7yrs	DKK 19.80m	0.0049% DKK 4.5m
Mijke Zachariasse	Senior Director	no data	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 800.00k	0.00013% DKK 119.7k
Rayne Waller	Executive VP & CTO	less than a year	no data	no data
Andrew Carlsen	Senior Director	no data	no data	no data

7.4yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 0MGB's management team is seasoned and experienced (7.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.8yrs	DKK 800.00k	0.00061% DKK 561.8k
Mijke Zachariasse	Senior Director	5.7yrs	DKK 1.10m	0.00083% DKK 764.4k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.8yrs	DKK 800.00k	0.00013% DKK 119.7k
Anders Pedersen	Non-Independent Director	21yrs	DKK 1.70m	0.011% DKK 10.6m
Elizabeth O'Farrell	Independent Director	2.7yrs	DKK 1.90m	no data
Deirdre Connelly	Independent Chairman of the Board	7.7yrs	DKK 2.80m	0.0091% DKK 8.3m
Rolf Hoffmann	Independent Director	7.7yrs	DKK 1.50m	0.0053% DKK 4.9m
Pernille Erenbjerg	Independent Deputy Chairman	9.8yrs	DKK 2.10m	0.0076% DKK 7.0m
Paolo Paoletti	Independent Director	9.8yrs	DKK 1.50m	0.0033% DKK 3.0m

7.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 0MGB's board of directors are considered experienced (7.7 years average tenure).

Genmab Management

Management criteria checks 4/4

Key information

Recent management updates

Genmab A/S Announces Executive Changes

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Genmab A/S, Annual General Meeting, Mar 13, 2024

Co-Founder recently sold kr.58m worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: kr.19.94 (vs kr.32.60 in 3Q 2023)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022)

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 17%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021)

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

First quarter 2022 earnings released: EPS: kr.7.10 (vs kr.16.76 in 1Q 2021)

Genmab A/S Revises Earnings Guidance for 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure